Pages that link to "Q42226115"

The following pages link to Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study (Q42226115):

Displaying 42 items.

• The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment (Q26795559) (← links)
• Hepatitis C virus infection (Q30235491) (← links)
• Direct-acting antivirals for chronic hepatitis C. (Q34557595) (← links)
• Clinical impact of treatment timing for chronic hepatitis C infection: a decision model (Q35889164) (← links)
• Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt (Q36256411) (← links)
• Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir (Q36663835) (← links)
• Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens (Q37116816) (← links)
• Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes (Q37223591) (← links)
• Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir (Q37726632) (← links)
• Extrahepatic manifestations in chronic hepatitis C virus carriers (Q38388423) (← links)
• Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace (Q38515906) (← links)
• Safety of direct antiviral agents in the management of hepatitis C. (Q38818416) (← links)
• Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial (Q38839784) (← links)
• Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues (Q39002714) (← links)
• Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. (Q39574126) (← links)
• An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens (Q39883996) (← links)
• Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus (Q39911124) (← links)
• Efficacy and safety of sofosbuvir-based, interferon-free therapy : The Management of rheumatologic extrahepatic manifestations associated with chronic hepatitis C virus infection. (Q40088333) (← links)
• Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study (Q40215825) (← links)
• Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2. (Q40343824) (← links)
• Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries (Q40414089) (← links)
• Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients (Q40604753) (← links)
• High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens (Q40750705) (← links)
• Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States (Q41366537) (← links)
• Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study). (Q41460664) (← links)
• The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study (Q41682696) (← links)
• Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials (Q42173527) (← links)
• Quality of life in Brazilian patients with treated or untreated chronic hepatitis C. (Q47135106) (← links)
• Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. (Q47404164) (← links)
• Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. (Q47548382) (← links)
• Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia (Q47605707) (← links)
• Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens (Q48070441) (← links)
• Development and Pilot-Testing of a Cognitive Behavioral Coping Skills Group Intervention for Patients with Chronic Hepatitis C. (Q53513928) (← links)
• Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life. (Q54258327) (← links)
• Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study. (Q55050518) (← links)
• Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges (Q57162382) (← links)
• A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study (Q57173478) (← links)
• Direct-acting antivirals for chronic hepatitis C (Q57389418) (← links)
• Improving hepatitis C direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived-experience (Q57469088) (← links)
• The Impact of Hepatitis C Virus Direct-Acting Antivirals on Patient-Reported Outcomes: A Dutch Prospective Cohort Study (Q58801171) (← links)
• Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir (Q60303567) (← links)
• What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection? (Q91656302) (← links)